Tonix Pharmaceuticals Holding Corp. (TNXP): Total Assets
$277.17M
As of 2025-12-31
$254.09M
As of 2026-06-30
+7.1%
3-year compound annual growth
+23.1%
5-year compound annual growth
+19.4%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $277.17M | +70.2% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $162.89M | +5.5% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $154.46M | -31.6% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $225.69M | -6.3% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $240.90M | +145.4% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $98.18M | +574.4% | 2022-03-14, Balance as of period end |
| 2019-12-31 | $14.56M | -44.7% | 2021-03-15, Balance as of period end |
| 2018-12-31 | $26.32M | -1.6% | 2020-03-24, Balance as of period end |
| 2017-12-31 | $26.75M | -2.7% | 2019-03-18, Balance as of period end |
| 2016-12-31 | $27.51M | -41.5% | 2018-03-09, Balance as of period end |
| 2015-12-31 | $47.02M | +18.9% | 2017-04-13, Balance as of period end |
| 2014-12-31 | $39.54M | +352.6% | 2016-03-03, Balance as of period end |
| 2013-12-31 | $8.74M | +312.7% | 2015-02-27, Balance as of period end |
| 2012-12-31 | $2.12M | +397.6% | 2014-03-28, Balance as of period end |
| 2011-12-31 | $425.4K | +131.2% | 2013-11-22, Balance as of period end |
| 2010-12-31 | $184.0K | n/a | 2012-03-30, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $277.17M | +70.2% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $224.95M | +195.8% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $6.96M | -12.2% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $21.44M | -9.2% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $91.52M | -41.8% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $94.62M | -28.2% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $141.31M | -19.5% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $50.24M | +36.3% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $38.32M | -28.3% |
Compare TNXP, EVMN, CVSI, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗